(Q38003214)

26 August 2017

title

Natural history of chronic hepatitis B: what exactly has REVEAL revealed? (English)

1 reference

26 August 2017

1 reference

1 reference

1

Uchenna H Iloeje

1 reference

26 August 2017

2

Hwai-I Yang

1 reference

26 August 2017

3

Chien-Jen Chen

1 reference

26 August 2017

language of work or name

1 reference

17 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

32

1 reference

26 August 2017

issue

9

1 reference

26 August 2017

page(s)

1333-1341

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Epidemiology of hepatitis B virus infection in the Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Global epidemiology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Long-term outcomes in hepatitis B: the REVEAL-HBV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Seropositivity of hepatitis B e antigen and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

How to predict HCC development in patients with chronic B viral liver disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

National Institutes of Health consensus development conference statement: management of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Natural history of chronic hepatitis B REVEALed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

The clinical significance of persistently normal ALT in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Pancreatic involvement in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2012.02805.X

10.1111/J.1478-3231.2012.02805.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference